Dong Bao Nan, Song Jie, Yang Wen Li, Zhan Hui, Luan Ting, Wang Jian Song
Urology Surgery Department, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
World J Oncol. 2024 Aug;15(4):625-639. doi: 10.14740/wjon1866. Epub 2024 Jul 5.
Earlier studies have juxtaposed different laparoscopic methods for treating renal tumors; however, extensive evidence with a particular focus on large kidney tumors remains lacking. The objective of this meta-analysis was to assess the perioperative outcomes, kidney performance, and cancer-related results of laparoscopic partial nephrectomy (LPN) versus laparoscopic radical nephrectomy (LRN) for treating extensive, localized, non-metastatic kidney tumors (cT1b-cT2N0M0).
We systematically searched multiple databases from database inception until December 2023 for relevant studies. Selected data were analyzed with the Cochrane Collaboration's Review Manager 5.4 software using a random-effects model. Outcomes were expressed as odds ratios and weighted mean differences with 95% confidence intervals, considering a P value of < 0.05 as significant.
Data from nine studies encompassing 1,303 patients (529 LPN, 774 LRN) revealed that LPN was associated with lengthier surgeries and increased blood loss compared to LRN. While LPN exhibited higher postoperative complication rates, the disparity did not reach statistical significance. LPN led to improved postoperative renal function, manifesting as a reduced estimated glomerular filtration rate (eGFR) decline and fewer incidents of new chronic kidney disease cases. Both groups demonstrated comparable tumor recurrence and overall mortality rates, but LPN exhibited significantly lower cancer-specific mortality rates.
LPN, despite longer operative times and greater intraoperative blood loss, was found to be superior to LRN in preserving postoperative renal function. Oncologically, LPN and LRN have comparable overall mortality rates, but LPN showed a significant advantage in terms of lower cancer-specific mortality rates.
早期研究对不同的腹腔镜治疗肾肿瘤方法进行了比较;然而,仍缺乏针对大肾肿瘤的广泛证据。本荟萃分析的目的是评估腹腔镜肾部分切除术(LPN)与腹腔镜根治性肾切除术(LRN)治疗广泛、局限性、非转移性肾肿瘤(cT1b - cT2N0M0)的围手术期结局、肾功能及癌症相关结果。
我们系统检索了多个数据库,从数据库建立至2023年12月,查找相关研究。使用Cochrane协作网的Review Manager 5.4软件,采用随机效应模型对所选数据进行分析。结果以比值比和加权平均差表示,并给出95%置信区间,将P值<0.05视为具有统计学意义。
来自9项研究的1303例患者(529例行LPN,774例行LRN)的数据显示,与LRN相比,LPN手术时间更长,失血更多。虽然LPN术后并发症发生率较高,但差异未达到统计学意义。LPN可改善术后肾功能,表现为估计肾小球滤过率(eGFR)下降减少,新的慢性肾病病例减少。两组的肿瘤复发率和总死亡率相当,但LPN的癌症特异性死亡率显著较低。
尽管LPN手术时间较长,术中失血较多,但在保留术后肾功能方面优于LRN。在肿瘤学方面,LPN和LRN的总死亡率相当,但LPN在降低癌症特异性死亡率方面具有显著优势。